DFTX Latest Press Releases

-- September 14, 2026 --

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder Business Wire 7:00 AM

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 6:00 AM

-- September 13, 2026 --

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Business Wire 5:00 PM

-- September 10, 2026 --

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 Business Wire 7:00 AM

-- September 8, 2026 --

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results Business Wire 7:00 AM

-- August 31, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM

-- August 26, 2026 --

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events Business Wire 7:01 AM

-- August 17, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM

-- August 12, 2026 --

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder Business Wire 7:00 AM

-- August 6, 2026 --

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Business Wire 4:01 PM

-- August 5, 2026 --

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout Globe Newswire 10:25 AM

-- August 3, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM

-- July 30, 2026 --

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire 4:01 PM

-- July 20, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM

-- July 16, 2026 --

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology Business Wire 7:00 AM

-- July 14, 2026 --

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD) Business Wire 7:00 AM

-- July 6, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM

-- June 30, 2026 --

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity Globe Newswire 9:00 AM

-- June 26, 2026 --

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PRNewswire 9:30 AM

-- June 25, 2026 --

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares Business Wire 4:15 PM

-- June 23, 2026 --

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering Business Wire 9:57 PM

-- June 22, 2026 --

Definium Therapeutics, Inc. Announces Proposed Public Offering Business Wire 4:01 PM

Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Business Wire 7:00 AM

-- June 21, 2026 --

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 Business Wire 5:00 PM

-- June 15, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM

-- June 1, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM

-- May 21, 2026 --

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference Business Wire 7:00 AM

-- May 12, 2026 --

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder Business Wire 7:00 AM

-- May 11, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM

-- May 7, 2026 --

Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Business Wire 4:01 PM

-- April 30, 2026 --

Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 Business Wire 4:01 PM

-- April 22, 2026 --

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day Business Wire 4:15 PM

-- April 20, 2026 --

Definium Therapeutics Announces New Employee Inducement Grants Business Wire 4:01 PM